Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention

Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Erenumab (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms STRIVE
  • Sponsors Amgen
  • Most Recent Events

    • 30 Sep 2021 Results of a pooled analysis assessing the risk of hypertension in patients with migraine who received Erenumab in clinical trials (NCT02066415 and NCT01952574) and two Phase 3 (NCT02456740 and NCT02483585) and in the postmarketing setting published in the Headache
    • 18 Aug 2021 Results of post-hoc analysis of two studies (NCT02456740 & NCT02066415) assessing effect of erenumab 70 and 140 mg on migraine pain, published in the Cephalalgia.
    • 06 Jun 2021 Results of a pooled analysis from following clinical studies: from two phase 2 ; NCT02066415, NCT01952574 and two Phase 3 ; NCT02456740 and NCT02483585 assessing Erenumab 70 and 140 mg versus placebo for migraine prevention presented at the 63rd Annual Scientific Meeting of the American Headache Society
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top